Flow cytometry platform from LeukoDx secures investment commitments of up to $8M

Flow cytometry platform developer LeukoDx (Jerusalem, Israel) has entered into agreements for investments totaling up to $8 million over the next three years, which should enable the company to take developing its Point of Care flow cytometry platform to the registration stage.

The initial $1.6 million tranche of funding was closed with a US-based private equity group and support from a European life science investor, as well as from historical investors. The remainder of the investment is subject to validation of agreed-upon milestones, which are planned to be reached over the next two years.

In securing the financing, the company can now focus its efforts on rolling out the platform's final development stages and perform its initial tests, states Julien Meissonnier, LeukoDx president and CEO. With the platform, the company aims to deliver flow cytometry in-vitro diagnostics (IVD) test results in 10 minutes from a single drop of blood on an automated disposable cartridge, he says.

Among the potential assays to be included to measure white blood cell activity is CD64 neutrophil activation, which is being developed under exclusive license from Trillium Diagnostics for detecting and monitoring infections and sepsis. The device will allow for rapid clinical decision-making in patient settings such as neonatal and intensive care units, emergency departments, and in remote locations lacking access to diagnostic medical laboratories. The company is seeking collaboration and partnership with biotechnology and IVD companies to broaden the range of test candidates to be implemented on its platform.


Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow OptoIQ on your iPhone; download the free app here.

Subscribe now to BioOptics World magazine; it's free!

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Will biophotonics win XCHALLENGE-1?

I’m waiting expectantly for next week. That’s when the results of the first of Nokia’s two consecutive Sensing XCHALLENGE competitions will be announced, during the Health 2.0 Fall Conference.


How will the United States' fiscal struggles impact biophotonics development and the life sciences driven by these technologies?

A benefits-rich approach to bio-optics commercialization

To my mind, the excitement of biophotonics research is surpassed only by its transfer to the larger world, where it can benefit humanity.

Photoacoustic method measures blood cell oxygen in real time

Washington University in St. Louis (WUSTL) biomedical researcher Lihong Wang, PhD, and colleagues have developed a photoacoustic method to measure oxygen in individual red blood cells in real time.


Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS